These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36772966)
1. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. Scarpetti L; Oturkar CC; Juric D; Shellock M; Malvarosa G; Post K; Isakoff S; Wang N; Nahed B; Oh K; Das GM; Bardia A Oncologist; 2023 Apr; 28(4):358-363. PubMed ID: 36772966 [TBL] [Abstract][Full Text] [Related]
2. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. Mishra AK; Abrahamsson A; Dabrosin C Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer. Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773 [TBL] [Abstract][Full Text] [Related]
4. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer. Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324 [TBL] [Abstract][Full Text] [Related]
5. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. Mukhopadhyay UK; Oturkar CC; Adams C; Wickramasekera N; Bansal S; Medisetty R; Miller A; Swetzig WM; Silwal-Pandit L; Børresen-Dale AL; Creighton CJ; Park JH; Konduri SD; Mukhopadhyay A; Caradori A; Omilian A; Bshara W; Kaipparettu BA; Das GM J Natl Cancer Inst; 2019 Nov; 111(11):1202-1215. PubMed ID: 30990221 [TBL] [Abstract][Full Text] [Related]
6. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946 [TBL] [Abstract][Full Text] [Related]
7. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412 [TBL] [Abstract][Full Text] [Related]
8. Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERβ Agonists. Schmitz V; Bauerschmitz G; Gallwas J; Gründker C Anticancer Res; 2022 Nov; 42(11):5187-5194. PubMed ID: 36288854 [TBL] [Abstract][Full Text] [Related]
9. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer. Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879 [TBL] [Abstract][Full Text] [Related]
10. Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer. Alexandrova E; Lamberti J; Saggese P; Pecoraro G; Memoli D; Cappa VM; Ravo M; Iorio R; Tarallo R; Rizzo F; Collina F; Cantile M; Bonito MD; Botti G; Nassa G; Weisz A; Giurato G Cells; 2020 Apr; 9(4):. PubMed ID: 32260128 [TBL] [Abstract][Full Text] [Related]
11. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer. Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337 [TBL] [Abstract][Full Text] [Related]
12. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function. Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822 [TBL] [Abstract][Full Text] [Related]
13. Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer. Alexandrova E; Giurato G; Saggese P; Pecoraro G; Lamberti J; Ravo M; Rizzo F; Rocco D; Tarallo R; Nyman TA; Collina F; Cantile M; Di Bonito M; Botti G; Nassa G; Weisz A Mol Cell Proteomics; 2020 Feb; 19(2):245-260. PubMed ID: 31792072 [TBL] [Abstract][Full Text] [Related]
14. Drivers and suppressors of triple-negative breast cancer. Wu W; Warner M; Wang L; He WW; Zhao R; Guan X; Botero C; Huang B; Ion C; Coombes C; Gustafsson JA Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34389675 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells. Hinsche O; Girgert R; Emons G; Gründker C Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519 [TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells. Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210 [TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer. Salahuddin A; Ghanem H; Omran GA; Helmy MW Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988 [TBL] [Abstract][Full Text] [Related]
19. Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. Goto Y; Thike AA; Ong CCH; Lim JX; Md Nasir ND; Li H; Koh VCY; Chen XY; Yeong JPS; Sasano H; Tan PH J Clin Pathol; 2020 Mar; 73(3):147-153. PubMed ID: 31563883 [TBL] [Abstract][Full Text] [Related]
20. Knockdown of PTEN decreases expression of estrogen receptor β and tamoxifen sensitivity of human breast cancer cells. Treeck O; Schüler-Toprak S; Skrzypczak M; Weber F; Ortmann O Steroids; 2020 Jan; 153():108521. PubMed ID: 31604073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]